Modified-Release Drug Delivery Technology
定  價:NT$6500元
優惠價: 95850
可得紅利積點:175 點




This two volume Second Edition describes the anatomical, physiological, pharmaceutical, and technological aspects of delivery routes, found in areas like:

  • Oral
  • Ocular
  • Dermal and transdermal
  • Vaginal
  • Colonic
  • Oral mucosal
  • Nasal
  • Pulmonary

Providing insight and critical assessment of the many available and emerging modified release drug delivery systems for their current and future value, topics include:

  • modified drug release landscape; academic, regulatory, and intellectual property viewpoints
  • I-vation Sustained Release Intravitreal System
  • ViaNase Intranasal Device and controlled particle dispersion technology Platform
  • Microneedles for drug delivery, PassPort system, Dot-Matrix technology, ultrasound, iontophoretic and technologies, DiretcHaler Nasal technology, intravaginal ring systems, Supravail, Vagisite, C-Vad? Vaginal Insert, and ‘Smart’ Vaginal Delivery Systems
  • the AERxR Pulmonary Drug Delivery System
  • AAD-Adaptive aerosol delivery technology
  • nebulizer technologies and dry powder inhaler systems

MICHAEL J. RATHBONE is Director, Research and Development, and General Manager of InterAg, a Division of DEC International NZ Limited, Hamilton, New Zealand. Dr. Rathbone received his Ph.D. in Pharmaceutical Science from the University of Aston, Birmingham, England, and has innovated many novel modified-release drug delivery systems, several of which have been commercialized. Dr. Rathbone has written over 35 peer-reviewed articles, has licensed five US patents and has edited or co-edited three books and numerous special issues of journals.

JONATHAN HADGRAFT is Professor of Biophysical Chemistry, University of London, United Kingdom. Dr. Hadgraft received his D.Phil. in Chemistry and his D.Sc. in Medicine from the University of Oxford, United Kingdom. His major research interests are in the application of physical chemistry to drug delivery, with special reference to the skin. He has been elected to Fellowships of the Royal Society of Chemistry and the American Association of Pharmaceutical Scientists, and has contributed to over 500 publications. He has contributed numerous book chapters and has co-edited several books. He serves on a number of editorial boards of pharmaceutical science journals.

MICHAEL S. ROBERTS is Professor, School of Medicine, University of Queensland, Brisbane, Australia; Senior Principal Research Fellow, National Health and Research Council; Director Therapeutics Research Unit, Princess Alexandra Hospital, Queensland Australia; Adjunct Professor, University of Canberra, Australia; and Visiting Professor, University of Lyon, France. Dr. Roberts received his Ph.D. and D.Sc. from the University of Sydney, Australia, and his M.B.A. from the University of Queensland. Dr. Roberts has also written over 280 peer-reviewed articles, 36 chapters, and has edited or co-edited five books.

MAJELLA E. LANE is a lecturer in Pharmaceutics in the School of Pharmacy, University of London, United Kingdom. She received her Ph.D. from Trinity College, Dublin, Ireland, and spent a sabbatical period at the University of Michigan, Ann Arbor, where she holds a Visiting Associate Scientist appointment. Her current research interests include development of vaccine dosage forms, formulation of peptides, transdermal drug delivery and mucosal drug delivery, and modeling of absorption processes across epithelial barriers.